A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
Status: Recruiting
Location: See all (53) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
• Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
• Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.
Locations
United States
Alabama
Cahaba Dermatology Skin Health Center
RECRUITING
Birmingham
Velocity Clinical Research, Mobile
RECRUITING
Mobile
California
Center for Dermatology Clinical Research
RECRUITING
Fremont
Antelope Valley Clinical Trials
RECRUITING
Lancaster
Northridge Clinical Trials
RECRUITING
Northridge
NorthBay Clinical Research
RECRUITING
Santa Rosa
Integrated Research of Inland
RECRUITING
Upland
FOMAT Medical Research
RECRUITING
Ventura
Florida
AMR Fort Myers
RECRUITING
Fort Myers
Advanced Clinical Research Institute
RECRUITING
Tampa
Iowa
The Iowa Clinic
RECRUITING
West Des Moines
Illinois
Sneeze, Wheeze & Itch Associates LLC
RECRUITING
Normal
Indiana
The Indiana Clinical Trials Center
RECRUITING
Plainfield
Kansas
Hutchinson Clinic
RECRUITING
Hutchinson
Kentucky
Bluegrass Allergy Care
RECRUITING
Lexington
Delricht Research Louisville
RECRUITING
Louisville
Louisiana
Delricht Research Louisiana
RECRUITING
Baton Rouge
Velocity Clinical Research, Lafayette
RECRUITING
Lafayette
Delricht Research
RECRUITING
New Orleans
Massachusetts
Boston Specialists
RECRUITING
Boston
Maryland
Johns Hopkins Bayview Medical Center
RECRUITING
Baltimore
Michigan
MI Skin Innovations
RECRUITING
Northville
Missouri
DelRicht Research - Town Center Dermatology
RECRUITING
Wildwood
North Carolina
Allergy Partners Clinical Research
RECRUITING
Asheville
Delricht Research - Priority Care
RECRUITING
Charlotte
Piedmont Healthcare
RECRUITING
Statesville
New York
Vitality Clinical Trials
RECRUITING
Woodbury
Ohio
DOCS Dermatology Research
RECRUITING
Bexley
Optima Research Boardman
RECRUITING
Boardman
Bernstein Clinical Research Center
RECRUITING
Cincinnati
Toledo Institute of Clinical Research
RECRUITING
Toledo
South Carolina
AMR Myrtle Beach
RECRUITING
Myrtle Beach
National Allergy and Asthma Research
RECRUITING
North Charleston
Tennessee
Delricht Research Smyrna
RECRUITING
Smyrna
Texas
Austin Regional Clinic ARC Clinical Research
RECRUITING
Austin
Studies in Dermatology
RECRUITING
Cypress
Western Sky Medical Research
RECRUITING
El Paso
Delricht Research - Lockhard Matter Dermatology
RECRUITING
Prosper
Utah
AMR Utah
RECRUITING
Layton
Washington
Seattle Clinical Research Center
RECRUITING
Seattle
Wisconsin
Allergy, Asthma, and Sinus Center
RECRUITING
Greenfield
Other Locations
Canada
Dandelion Allergy Centre
RECRUITING
Mississauga
Centre de Recherche Saint-Louis - Montréal
RECRUITING
Montreal
Allergy Research Canada
RECRUITING
Niagara Falls
Red Maple Trials
RECRUITING
Ottawa
Centre de Recherche Saint-Louis
RECRUITING
Québec
Japan
Mita Dermatology
COMPLETED
Minato-ku
Dermatology and Ophthalmology Kume Clinic
RECRUITING
Sakai
ThinkPark Dermatology Clinic
RECRUITING
Shinagawa-ku
Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
RECRUITING
Tachikawa
Osaka Medical and Pharmaceutical University Hospital
RECRUITING
Takatsuki
Yoshikawa Skin Clinic
RECRUITING
Takatsuki
Ikebukuro Nishiguchi Fukurou Dermatology
COMPLETED
Toshima-ku
Contact Information
Primary
Polina Bukshpun
polina.bukshpun@evommune.com
+1-818-536-2358
Time Frame
Start Date: 2025-03-20
Estimated Completion Date: 2026-05
Participants
Target number of participants: 160
Treatments
Experimental: Dose 1
Orally administered EVO756, dose 1
Experimental: Dose 2
Orally administered EVO756, dose 2
Experimental: Dose 3
Orally administered EVO756, dose 3
Placebo_comparator: Placebo control
Orally administered placebo control
Related Therapeutic Areas
Sponsors
Leads: Evommune, Inc.